Recent news on Factor Ix

Neose Receives Milestone Payment From Novo Nordisk on Factor IX ...  -  May 24, 2007
Business Wire (press release),Factor IX products are used in the treatment of Hemophilia B. Hemophilia B, also known as Christmas Disease, is caused by a deficiency of a blood plasma

Guidelines Updated for Treatment of Spontaneous Intracerebral ...  -  May 3, 2007
Medscape (subscription)Prothrombin complex concentrate, factor IX complex concentrate, and recombinant activated factor VII normalize the laboratory elevation of the international

Biogen Idec Reports First Quarter 2007 Results  -  May 2, 2007
PharmaLive.com (press release),...to as much as $124 million if certain development milestones with respect to Syntonix's lead product, long acting recombinant Factor IX, are achieved.

Wyeth Receives FDA Approval for New BeneFIX Features That Provide ...  -  Mar 29, 2007
Drug Newswire (press release),BeneFIX is a coagulation factor created using recombinant DNA technology to replace clotting factor IX to stop or prevent bleeding in people with hemophilia

Daily pill to beat genetic diseases  -  Apr 23, 2007
Times Online,In haemophilia, it is the gene for the clotting agents factor VIII or factor IX that is disrupted. PTC124 works by binding to a part of the cell called the

Blood clotting protein extracted from pig milk  -  Apr 12, 2007
China Post,ATIT officials explained that the protein they extracted is identical to the human clotting factor IX, which is used in treating hemophilia type B.

IndyCar Racer Marco Andretti Drives Support for Hemophilia ...  -  Apr 6, 2007
PR Web (press release),Hemophilia B is characterized by deficient or defective factor IX. The NHF is dedicated to finding better treatments and cures for bleeding and clotting

IndyCar Racer Marco Andretti Drives Support for Hemophilia ...  -  Apr 4, 2007
PR Newswire (press release),Hemophilia B is characterized by deficient or defective factor IX. About the National Hemophilia Foundation The NHF is dedicated to finding better

Nautilus Biotech Begins Phase I Clinical Trial In The USA For ...  -  Apr 3, 2007
Medical News Today (press release),Interferon gamma, Clotting Factor IX (in collaboration with Wyeth Pharmaceuticals) and HMGB1 (in collaboration with Creabilis Therapeutics).

BeneFix Enhancements Approved  -  Mar 28, 2007
Facts and Comparisons,The FDA has approved several product enhancements for Wyeth Pharmaceutical’s BeneFix coagulation factor IX (recombinant). Patients who use the most common

Wyeth Receives FDA Approval for New BeneFIX Features That Provide ...  -  27 Mar 2007
PipelineReview.com (press release),BeneFIX is a coagulation factor created using recombinant DNA technology to replace clotting factor IX to stop or prevent bleeding in people with hemophilia

Pain Therapeutics Licenses Biotechnology To Treat Rare Disorder  -  Mar 22, 2007
PR Newswire (press release),People with hemophilia are deficient in the key proteins-Factor VIII (hemophilia A) or Factor IX (hemophilia B)- that are vital to prevent uncontrolled

CSL Behring's Helixate(R) FS and Mix2Vial(TM) Now Packaged ...  -  Feb 25, 2007
Drug Newswire (press release),Hemophilia B is characterized by deficient or defective factor IX. CSL Behring is a global leader in the plasma protein biotherapeutics industry.

BioSante Pharmaceuticals Reports Product Development Highlights ...  -  Mar 9, 2007
Nanotechnology News (press release)BioSante continued work under its subcontract with the University of Nebraska for the development of recombinant Factor IX formulations using CaP for

No go for Novo's potential stroke therapy  -  Feb 28, 2007
DrugResearcher.com,ReFacto is based on Factor VIII and BeneFix on Factor IX. In a separate announcement, Novo recently said it will provide a "significant unrestricted grant

Inovio's New Website Supports Novel Gene Expression Technology  -  Mar 9, 2007
BioResearch Online (press release),...protein deficiency diseases such as anemia, which results from erythropoietin (EPO) deficiency, and hemophilia, which results from factor IX deficiency.

Nautilus Biotech announces IND filing for Belerofon, its oral ...  -  Feb 28, 2007
PipelineReview.com (press release),Interferon gamma, Clotting Factor IX (in collaboration with Wyeth Pharmaceuticals) and HMGB1 (in collaboration with Creabilis Therapeutics).

CSL Behring's Helixate(R) FS and Mix2Vial(TM) Now Packaged ...  -  Feb 20, 2007
Earthtimes.org...classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX.

Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration ...  -  Feb 5, 2007
netPR.pl (komunikaty prasowe),Nautilus Biotech today announced the signing of a research collaboration and license agreement to discover and develop novel recombinant Factor IX proteins

CSL Behring's Helixate(R) FS and Mix2Vial(TM) Now Packaged ...  -  Feb 20, 2007
PR Newswire (press release),Hemophilia B is characterized by deficient or defective factor IX. CSL Behring is a global leader in the plasma protein biotherapeutics industry.

Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration ...  -  Feb 5, 2007
Earthtimes.orgPeople with hemophilia are deficient in one of the key proteins - either Factor VIII (hemophilia A) or Factor IX (hemophilia B) - that are vital in the

Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration ...  -  Feb 5, 2007
PR Newswire (press release),Wyeth currently markets the only recombinant Factor IX product, BeneFIX(R) Coagulation Factor IX (Recombinant). As part of the agreement, Nautilus Biotech

EU-Approval For Continuous Infusion Of KOGENATE® Bayer  -  Feb 12, 2007
Medical News Today (press release),Hemophilia B is characterized by deficient or defective factor IX. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading,

Wyeth, Nautilus Biotech in research collaboration  -  Feb 5, 2007
Pharmaceutical Business ReviewWyeth Pharmaceuticals and Nautilus Biotech have entered into a research collaboration and license agreement to develop recombinant Factor IX proteins for

Wyeth Inks Two Deals to Improve Hemophilia Program  -  Feb 5, 2007
Genetic Engineering News (press release),Wyeth reports that it currently markets the only recombinant Factor IX product, BeneFIX Coagulation Factor IX (recombinant). The research collaboration with

Biogen Idec acquires Brandeis spin-out  -  Jan 31, 2007
EurekAlert (press release),Syntonix's lead product, FIX:Fc, is a proprietary long-acting factor IX product for the treatment of hemophilia B. It has the potential to reduce the

EU-Approval for Continuous Infusion of KOGENATE(R) Bayer  -  Feb 9, 2007
PipelineReview.com (press release),Hemophilia B is characterized by deficient or defective factor IX. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading,

Wyeth Pharmaceuticals and MediVas Announce Research Partnership to ...  -  Feb 6, 2007
PipelineReview.com (press release),People with hemophilia are deficient in one of the key proteins – either Factor VIII (hemophilia A) or Factor IX (hemophilia B) – that are vital in the

Wyeth Pharmaceuticals and MediVas Announce Research Partnership to ...  -  Feb 5, 2007
PR Newswire (press release),People with hemophilia are deficient in one of the key proteins -- either Factor VIII (hemophilia A) or Factor IX (hemophilia B) -- that are vital in the

Wyeth Pharmaceuticals and MediVas Announce Research Partnership to ...  -  Feb 5, 2007
Earthtimes.orgPeople with hemophilia are deficient in oneof the key proteins - either Factor VIII (hemophilia A) or Factor IX(hemophilia B) - that are vital in the

Wyeth boosts pipeline with three deals  -  Feb 8, 2007
In-PharmaTechnologist.com,It is a blood-clotting disorder caused by a deficiency in one of two proteins - Factor VIII (haemophilia A) or Factor IX (haemophilia B).

Wyeth pens three deals in a day  -  Feb 6, 2007
In-PharmaTechnologist.com,Through another collaboration deal, this time with French company, Nautilus Biotech, Wyeth hopes to develop longer-lasting Factor IX proteins to treat

Wyeth Pharmaceuticals, France's Nautilus Biotech in hemophilia B ...  -  Feb 5, 2007
ABCmoney.co.uk,Patients with the blood-clotting disorder hemophilia A or hemophilia B are dependent on protein replacement therapy with Factor VIII or Factor IX

State ranks high in disabled children  -  Feb 6, 2007
AL.com,Tristan has severe hemophilia B, a rare disorder that means his body makes little or no Factor IX, a clotting agent in blood, said his mother,

Wyeth Inks Deal With Nautilus Biotech  -  Feb 5, 2007
Houston Chronicle,Specifically, the research and and license agreement aims at developing recombinant Factor IX proteins to treat the hereditary blood disorder.

Biotech Day in Review: Wyeth and AstraZeneca Sign More Deals  -  Feb 6, 2007
Seeking Alpha,Wyeth also entered a partnership with Nautilus Biotech of France to discover novel recombinant Factor IX proteins for the treatment of hemophilia B. As with

Market Report -- In Play (WIRES)  -  Feb 5, 2007
MSN Money...announce the signing of a research collaboration and license agreement to discover and develop novel recombinant Factor IX proteins for the treatment of

Wyeth heads to Europe for two research agreements  -  Feb 5, 2007
Pharma Times (subscription),The second deal Wyeth has signed is with Nautilus Biotech, based in Evry, France, which will look to discover and develop novel recombinant Factor IX

Intas to offload 25% stake to fund expansion plans  -  18 Jan 2007
Myiris.com,Factor-IX protein is used to treat Hemophilia-B. The protein is extracted from the genetically-modified pig milk. As per the JV, IBL will develop the drugs

Biogen Idec to Acquire Syntonix  -  18 Jan 2007
Xtvworld (press release),Syntonix's lead product, FIX:Fc, is a proprietary long-acting factor IX product for the treatment of hemophilia B. It has the potential to reduce the

Biogen Idec Takes Over Syntonix for $40M  -  18 Jan 2007
Genetic Engineering News (press release),Syntonix' lead product, FIX:Fc, is a long-acting factor IX product for the treatment of hemophilia B. Syntonix expects to file an IND application for FIX:Fc

Intas to offload 25% stake to fund expansion  -  Jan 15, 2007
Business Standard,Factor-IX protein is used to treat Hemophilia-B. The protein is extracted from the genetically-modified pig milk. The pig is used as a bio-reactor which is

Intas Biopharmaceuticals joins hands with Progenetics  -  Jan 12, 2007
Moneycontrol.com,The first drug to be developed through this technology by Intas Biopharmaceuticals would be Factor IX which is used for the treatment of Hemophilia B,

Early diagnosis can lessen complications  -  Jan 1, 2007
Newindpress (subscription),These genes control ‘Factor VIII’ and ‘Factor IX’ which are responsible for coagulation of blood. So abnormalities in both the factors can cause haemophilia

Hospitals, Healthcare Providers to Save with Premier Plasma ...  -  Jan 3, 2007
dBusinessNews Charlotte (press release),Products include albumin; intravenous immunoglobulin (IVIG); hyperimmune globulin; various coagulation factor products including Factor VIII and Factor IX;

Biogen Idec buys Syntonix in deal worth up to $120 million  -  Jan 16, 2007
Pharma Times (subscription),Its lead product, FIX:Fc, is a proprietary long-acting factor IX product for the treatment of haemophilia B and the company expects to file a New Drug

Biotech Stocks Day-in-Review: BioCryst Gets Flu Drug Support  -  Jan 5, 2007
Seeking Alpha,FIX:Fc is a long-acting factor IX product for hemophilia B that will reduce the number of required injections. Biogen Idec paid $40 million upfront for

Decreased Bleeding Frequency With Secondary Prophylactic Use Of ...  -  Dec 13, 2006
Medical News Today (press release),Hemophilia patients who have inhibitors (or neutralizing antibodies) against clotting-replacement factor VIII or factor IX experience severe morbidity due

New anticoagulant with an "on-off" switch  -  Nov 28, 2006
TheHeart.Org,In this instance we chose to target factor IX, but we could also make RNA aptamer inhibitors targeting cancer cells or microbes or many other pathogens.

BTG in the black at half way stage  09 Nov 2006
The major contributor to recurring royalties was BeneFIX, the recombinant Factor IX product for haemophilia B, which generated gross royalties of £8m. ... -ShareCast, Chicago Doctor Helps Families Eradicate Genetic Disease  Nov 3, 2006
...clotting properly. It is caused by a mutation in a single gene that causes deficiency of a plasma protein called factor IX. Women ... -Yahoo! News (press release) March towards Molecular Medicine - I  Nov 6, 2006
...studies as well. An example is Hemophilia B, which is caused by a deficiency of clotting factor IX in the blood. The most notable ... -GreaterKashmir.com (press release), NovoSeven(R) Becomes First And Only Recombinant Therapy For ...  Oct 18, 2006
...in 1999, and is currently indicated for use in treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX and for ... -Medical News Today (press release), Grifols Launches PatientCare Program to Address Insurance Lapses ...  Oct 12, 2006
Grifols therapies used to treat both Hemophilia A (Factor VIII deficiency) and Hemophilia B (Factor IX deficiency) are covered under the PatientCare Program. ... -PR Newswire (press release), Nautilus Biotech Announces IND Filing for its Injectable Long ...  Oct 10, 2006
...profiles, including long lasting Interferon alpha (Belerofon(R)), hGH (Vitatropin(TM)), Interferon beta, Clotting Factor IX, Erythropoietin, Interferon gamma ... -Earthtimes.org Serono And Syntonix To Pursue The Development Of A Long-Acting ...  Sep 19, 2006
Syntonix’ lead product is a long-acting Factor IX product for the treatment of Hemophilia B, which is being developed in a strategic alliance with Biovitrum ... -PipelineReview.com

New anticoagulant with an "on-off" switch  -  Nov 28, 2006
TheHeart.Org,In this instance we chose to target factor IX, but we could also make RNA aptamer inhibitors targeting cancer cells or microbes or many other pathogens.

Nautilus Biotech And Creabilis Therapeutics Achieve Technical ...  -  Nov 15, 2006
PipelineReview.com (press release),...hGH (Vitatropin™), Interferon beta, Clotting Factor IX, Erythropoietin, Interferon gamma and HMG-B1; it has established a strong intellectual property

RECHERCHE RAPIDE PAR ORGANISME  -  Nov 14, 2006
CNW Telbec (Communiqués de presse),...including long lasting Interferon alpha (Belerofon(R)), hGH (Vitatropin(TM)), Interferon beta, Clotting Factor IX, Erythropoietin, Interferon gamma and

Neose Receives Research Milestone Payment from Novo Nordisk  Aug 3, 2006
Factor IX products are used in the treatment of Hemophilia B. Hemophilia B, also known as Christmas Disease, is caused by a deficiency of a blood plasma ... -PharmaLive.com

Bayer HealthCare Introduces Free Product Trial Program For ...  Jul 17, 2006
...either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX. Bayer HealthCare, a subsidiary ... -Genetic Engineering News

DOLLY AND ME: A TRUE STORY  Jul 8, 2006
But Polly was not just a cloned lamb. She was a genetically-transformed clone, able to secrete the human protein, Factor IX, which makes the blood clot. ... -Sunday Herald

Gene therapy may help Hemophilia A  Jul 3, 2006
One in 5,000 males lacks Factor VIII and develops hemophilia A, and one in 25,000 lacks Factor IX and develops hemophilia B or Christmas disease. ... -United Press International



Gene Therapy Shows Promise for Hemophilia  May 6, 2006
In a phase-I clinical trial for safety, three patients were given a dose of an AAV gene therapy vector containing the gene for factor IX. ... - About - News & Issues

BioSante Pharmaceuticals Reports Product Development Highlights ...  May 12, 2006
BioSante was awarded a subcontract by the University of Nebraska-Lincoln valued at $250,000 for the development of recombinant Factor IX formulations using ... - Genetic Engineering News

Dad fights for truth after HIV blunder  Apr 23, 2006
...clot properly. To treat this he was advised to take a 'miracle substance' known as Factor VIII and Factor IX concentrates. These ... - ic Wales





Unheard they bleed  Apr 3, 2006
They are caused by complete absence, decreased or defective production of important blood clotting proteins, factor VIII and factor IX respectively. ... - GreaterKashmir.com

Gene therapy gives hope to haemophiliacs  Mar 15, 2006
He received a cloned version of what's known as the Christmas disease gene, which expresses the blood-clotting agent Factor IX, deficient in some haemophiliacs ... - Sydney Morning Herald

BioSante Pharmaceuticals Reports Product Development Highlights ...  Mar 31, 2006
We received a subcontract for the development of recombinant Factor IX formulations for delivery of CaP via alternative routes of administration for the ... - Genetic Engineering News

Infant Euthanasia the Dutch Way  Mar 14, 2006
A long story short and a lot of doctor visits later, my son was diagnosed with not one but two VERY rare forms of hemophilia: Factor IX and Factor XI ... - Lone Star Times

Rockland students showcase science experiments  Mar 20, 2006
Danielle Rubin, Suffern High, "Aav-mediated Factor Ix Gene Transfer to Skeletal Muscle in Patients with Severe Hemophilia B" — 1st Place Science/Grade 10 ... - The Journal News.com

Mersana Therapeutics, Inc. Appoints Key Members of Management Team ...  Mar 21, 2006
Wyeth as head of clinical immunology and clinical pharmacology and was involved in the successful registration of Neumega (IL-11) in oncology and Factor IX. ... - PR Newswire

3rd Generation Andretti Will Race at Indianapolis 500 to Support ...  Feb 22, 2006
...is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX. Bayer HealthCare, a subgroup ... - Genetic Engineering News,

Research Highlights  Feb 22, 2006
Children's Hospital of Philadelphia, Pennsylvania, and her team injected sufferers with a modified virus carrying the gene for blood coagulation factor IX (F.IX ... - Nature.com (subscription),

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional